Use of Antibody

a technology of specific binding molecules and antibodies, applied in the direction of antibody medical ingredients, drug compositions, peptides, etc., can solve the problems of limiting the use of these drugs, and 30% of patients are refractory to pharmacotherapy
US20210079076A1Inactive Publication Date: 2021-03-18MEDANNEX LTD
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
US Ā· United States
Patent Type
Applications(United States)
Current Assignee / Owner
MEDANNEX LTD
Publication Date
2021-03-18
Estimated Expiration
Not applicable Ā· inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention provides a specific binding molecule that binds to Annexin-1 (Anx-A1) for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD. The invention also provides a pharmaceutical composition comprising a specific binding molecule of the invention for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD.
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF THE INVENTION

[0001] The present invention relates to the use of specific binding molecules, particularly antibodies and fragments thereof, which bind to annexin-A1, in the treatment of obsessive-compulsive disorder (OCD) and related diseases.BACKGROUND TO THE INVENTION

[0002] Obsessive compulsive disorder (OCD) is a chronic, relapsing psychiatric affliction with a lifetime prevalence of 1-3%. According to the Diagnostic and Statistical Manual of Mental Disorders (4th ed; DSM IV), the essential features of this disease are recurrent obsessions and / or compulsions (e.g., doubting, checking, washing) that are time consuming (i.e., they take more than 1 hour a day) or cause marked distress or significant impairment.

[0003] The most effective treatments for mental disorders like OCD are antipsychotic and behavioural treatments. Yet, around 30% of the patients are refractory to pharmaco- and behavioural therapy. In addition, side effects such as agranulocytosis (loss of the white blood...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More